Citadel Advisors
TTNP

Citadel Advisors’s Titan Pharmaceuticals TTNP Stock Holding History

Citadel Advisors’s Portfolio TTNP Stock Details TTNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-795
Closed -$30K – 14773
2021
Q3 		$30K Buy
795
+60
+8% +$2.63K ﹤0.01% 13572
2021
Q2 		$38K Sell
735
-545
-43% -$27.3K ﹤0.01% 13431
2021
Q1 		$76K Buy
+1,280
New +$84.7K ﹤0.01% 12681
2019
Q4 		– Sell
-24
Closed -$4K – 9785
2019
Q3 		$4K Sell
24
-63
-72% -$28.4K ﹤0.01% 9076
2019
Q2 		$67K Buy
87
+11
+14% +$10.1K ﹤0.01% 8653
2019
Q1 		$82K Buy
+76
New +$73.8K ﹤0.01% 8623
2016
Q3 		– Sell
-3
Closed -$65K – 7788
2016
Q2 		$65K Buy
+3
New +$63.9K ﹤0.01% 6343

Other funds holding TTNP

DS
DRW Securities Chicago, Illinois $7.21B AUM 20.54% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
CA
CoreCap Advisors Southfield, Michigan $3.39B AUM 31.21% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GWSA
Global Wealth Strategies & Associates Denver, Colorado $528M AUM 23.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citadel Advisors's TTNP Position: Q3 2025 in Review

Citadel Advisors sold out of Titan Pharmaceuticals (TTNP) in Q3 2025, closing a stake of 12,069 shares — an estimated $50.7K sold.

Citadel Advisors first reported a position in TTNP in Q2 2016 and held it in 12 quarters. The position peaked at $179K in Q2 2021. 18 funds tracked by Wall St. Rank hold TTNP as of Q3 2025.

  • Citadel Advisors reported no remaining Titan Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Citadel Advisors sold 12,069 Titan Pharmaceuticals shares in Q3 2025, an estimated $50.7K.
  • Citadel Advisors first reported a position in Titan Pharmaceuticals in Q2 2016 and held it in 12 quarters.
  • Citadel Advisors's Titan Pharmaceuticals position peaked at $179K in Q2 2021.
  • 18 funds tracked by Wall St. Rank held Titan Pharmaceuticals as of Q3 2025.

Based on Citadel Advisors's 13F filing for Q3 2025, filed 14 Nov 2025.